Most studies used rituximab (anti-CD20) to potentiate the NK cell response against B cell leukemias, in neuroblastoma ADCC can be triggered with anti-GD2, while in multiple myeloma daratumumab (anti-CD38) was used. This evidence concerns the gene CD38 and plasma cell myeloma.